{"id":14090,"date":"2026-09-01T17:12:32","date_gmt":"2026-09-01T15:12:32","guid":{"rendered":"https:\/\/www.afaf.asso.fr\/?p=14090"},"modified":"2026-09-01T17:12:36","modified_gmt":"2026-09-01T15:12:36","slug":"avis-sur-le-medicament-skyclarys-50mg-omaveloxolone-gelule-dans-lataxie-de-friedreich-chez-ladulte-et-ladolescent-a-partir-de-16-ans-par-la-commission-de-la-transparence-ct-de-la-ha","status":"publish","type":"post","link":"https:\/\/www.afaf.asso.fr\/2026\/09\/01\/avis-sur-le-medicament-skyclarys-50mg-omaveloxolone-gelule-dans-lataxie-de-friedreich-chez-ladulte-et-ladolescent-a-partir-de-16-ans-par-la-commission-de-la-transparence-ct-de-la-ha\/","title":{"rendered":"Avis sur le m\u00e9dicament SKYCLARYS 50mg (omav\u00e9loxolone), g\u00e9lule dans l\u2019Ataxie de Friedreich chez l&#8217;adulte et l&#8217;adolescent \u00e0 partir de 16 ans, par la Commission de la Transparence (CT) de la HAS du 8 juillet 2026"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">En septembre 2024, la Commission de la Transparence (CT) a rendu un avis favorable au remboursement de Skyclarys, lui accordant un <strong>Service M\u00e9dical Rendu (SMR) mod\u00e9r\u00e9<\/strong> (remboursement \u00e0 <strong>30%<\/strong> par l&#8217;Assurance Maladie) et une <strong>Am\u00e9lioration du<\/strong> <strong>Service M\u00e9dical Rendu<\/strong> <strong>(ASMR) V<\/strong> (absence de progr\u00e8s th\u00e9rapeutique).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">En mai 2026, la CT a r\u00e9alis\u00e9 une \u00e9valuation des nouvelles donn\u00e9es pr\u00e9sent\u00e9s par Biogen.\u00a0 <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Le 8 juillet 2026, la commission a proc\u00e9d\u00e9 \u00e0 l\u2019audition du laboratoire et \u00e0 l\u2019adoption de l\u2019avis d\u00e9finitif\u00a0: le <strong>SMR<\/strong> a \u00e9t\u00e9 revu \u00e0 la baisse passant de mod\u00e9r\u00e9 \u00e0 <strong>faible<\/strong> (remboursement de <strong>15%<\/strong> par l&#8217;Assurance Maladie) tandis que l\u2019<strong>ASMR V<\/strong> a \u00e9t\u00e9 maintenu.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">L\u2019AFAF tenait \u00e0 vous informer de ces informations importantes. Nous avons contribu\u00e9 \u00e0 chaque \u00e9valuation en fournissant les r\u00e9sultats de l\u2019enqu\u00eate r\u00e9alis\u00e9e aupr\u00e8s de malades atteints d\u2019AF en 2025. D&#8217;autre part, nous allons \u00e9changer avec les diff\u00e9rentes parties-prenantes et vous tiendrons inform\u00e9s de l&#8217;avancement des prochaines \u00e9tapes.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"has-text-color has-link-color has-large-font-size wp-elements-1 wp-block-paragraph\" style=\"color:#0852c9\"><strong>Les conclusions de la Commission de la Transparence<\/strong><\/p>\n\n\n\n<h3 class=\"wp-block-heading has-vivid-cyan-blue-color has-text-color has-link-color wp-elements-2\">1. Service M\u00e9dical Rendu <strong>(SMR)<\/strong><\/h3>\n\n\n\n<div class=\"wp-block-group is-vertical is-layout-flex wp-container-core-group-is-layout-4fc3f8e1 wp-block-group-is-layout-flex\">\n<div class=\"wp-block-group is-vertical is-layout-flex wp-container-core-group-is-layout-4fc3f8e1 wp-block-group-is-layout-flex\">\n<ul class=\"wp-block-list\">\n<li>L\u2019ataxie de Friedreich est une maladie neurog\u00e9n\u00e9tique rare, grave et invalidante. Les manifestations de la maladie ont des r\u00e9percussions importantes sur tous les aspects de la vie quotidienne, sur la vie familiale, sociale et professionnelle des patients.<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Il s\u2019agit d\u2019un traitement symptomatique qui vise \u00e0 ralentir le processus \u00e9volutif de la maladie.<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Le rapport efficacit\u00e9\/effets ind\u00e9sirables appara\u00eet limit\u00e9 \u00e0 court terme et reste \u00e0 pr\u00e9ciser \u00e0 plus long terme eu \u00e9gard au faible niveau de preuve et\/ou au manque de donn\u00e9es sur l\u2019\u00e9volution de la morbidit\u00e9 de la maladie, la qualit\u00e9 de vie et la survie des patients.<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Il s\u2019agit d\u2019un traitement de premi\u00e8re intention en l\u2019absence de comparateur cliniquement pertinent.<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"has-vivid-cyan-blue-color has-text-color has-link-color wp-elements-3\">Int\u00e9r\u00eat de sant\u00e9 publique<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Compte tenu : <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&#8211; du besoin m\u00e9dical majeur de disposer de m\u00e9dicaments efficaces et bien tol\u00e9r\u00e9s chez ces patients,<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&#8211; de l\u2019absence de r\u00e9ponse au besoin m\u00e9dical identifi\u00e9 en raison :<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><kbd>* <\/kbd>des incertitudes sur l\u2019impact du m\u00e9dicament quant \u00e0 la r\u00e9duction de la morbidit\u00e9 \u00e0 court terme, eu \u00e9gard aux r\u00e9sultats versus placebo sur le score d\u2019\u00e9valuation neurologique mFARS \u00e0 48 semaines de traitement,<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">*  de l\u2019absence d\u2019\u00e9l\u00e9ments permettant d\u2019\u00e9tayer un impact sur la qualit\u00e9 de vie, la morbidit\u00e9 \u00e0 long terme et\/ou la survie des patients,<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">*  de l\u2019absence d\u2019\u00e9l\u00e9ments permettant d\u2019\u00e9tayer un impact suppl\u00e9mentaire sur l\u2019organisation des soins ou le parcours de soin et\/ou de vie du patient et de son entourage,<\/p>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-group\"><div class=\"wp-block-group__inner-container is-layout-constrained wp-block-group-is-layout-constrained\">\n<ul class=\"wp-block-list\">\n<li>SKYCLARYS 50 mg (omav\u00e9loxolone) n\u2019est pas susceptible d\u2019avoir un impact suppl\u00e9mentaire sur la sant\u00e9 publique.<\/li>\n<\/ul>\n<\/div><\/div>\n\n\n\n<div class=\"wp-block-group\"><div class=\"wp-block-group__inner-container is-layout-constrained wp-block-group-is-layout-constrained\">\n<div class=\"wp-block-group is-vertical is-layout-flex wp-container-core-group-is-layout-4fc3f8e1 wp-block-group-is-layout-flex\">\n<p class=\"has-luminous-vivid-amber-background-color has-background has-medium-font-size wp-block-paragraph\"><strong>Compte tenu de l\u2019ensemble de ces \u00e9l\u00e9ments, la Commission consid\u00e8re que le service m\u00e9dical rendu par SKYCLARYS 50 mg (omav\u00e9loxolone), g\u00e9lule, est faible dans l\u2019indication de l\u2019AMM.<\/strong><\/p>\n\n\n\n<p class=\"has-luminous-vivid-amber-background-color has-background has-medium-font-size wp-block-paragraph\"><strong>La Commission donne un avis favorable \u00e0 l&#8217;inscription de SKYCLARYS 50 mg (omav\u00e9loxolone), g\u00e9lule, sur la liste des sp\u00e9cialit\u00e9s remboursables aux assur\u00e9s sociaux et sur la liste des sp\u00e9cialit\u00e9s agr\u00e9\u00e9es \u00e0 l\u2019usage des collectivit\u00e9s <sup>1<\/sup> dans l\u2019indication et aux posologies de l\u2019AMM.<\/strong><\/p>\n<\/div>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Taux de remboursement propos\u00e9 pour l\u2019inscription sur la liste des sp\u00e9cialit\u00e9s remboursables aux assur\u00e9s sociaux&nbsp;: 15%<\/li>\n<\/ul>\n<\/div><\/div>\n\n\n\n<h3 class=\"wp-block-heading has-vivid-cyan-blue-color has-text-color has-link-color wp-elements-4\">2. Am\u00e9lioration du Service M\u00e9dical Rendu <strong>(ASMR)<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Compte tenu :<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>des r\u00e9serves sur la pertinence clinique de l\u2019effet observ\u00e9 versus placebo sur le score d\u2019\u00e9valuation neurologique mFARS chez les patients sans d\u00e9formation \u00ab pieds creux \u00bb de l\u2019\u00e9tude MOXIe partie 2 (-2,4 points, IC95% [-4,31 ; -0,50]) et de l\u2019absence de mise en \u00e9vidence de diff\u00e9rence versus placebo sur les crit\u00e8res d\u2019\u00e9valuation secondaires hi\u00e9rarchis\u00e9s,<\/li>\n\n\n\n<li>des incertitudes sur la transposabilit\u00e9 des r\u00e9sultats \u00e0 l\u2019ensemble des patients ayant une ataxie de Friedreich, notamment aux patients ayant une cardiomyopathie avanc\u00e9e, un diab\u00e8te non contr\u00f4l\u00e9 ou une forme \u00e9volu\u00e9e de la maladie,<\/li>\n\n\n\n<li>des r\u00e9serves \u00e9mises sur le niveau de preuve et l\u2019interpr\u00e9tation des r\u00e9sultats issus des donn\u00e9es de comparaison indirecte,<\/li>\n\n\n\n<li>de la fr\u00e9quence des effets ind\u00e9sirables rapport\u00e9s et la mise en \u00e9vidence de risques de l\u00e9sion h\u00e9patique et d\u2019insuffisance cardiaque congestive,<\/li>\n\n\n\n<li>et malgr\u00e9 un besoin m\u00e9dical majeur de disposer de m\u00e9dicaments efficaces et bien tol\u00e9r\u00e9s chez ces patients,<\/li>\n<\/ul>\n\n\n\n<p class=\"has-luminous-vivid-amber-background-color has-background has-medium-font-size wp-block-paragraph\"><strong>La commission consid\u00e8re que SKYCLARYS 50 mg (omav\u00e9loxolone), g\u00e9lule, n\u2019apporte pas d\u2019am\u00e9lioration du service m\u00e9dical rendu (ASMR V) dans la strat\u00e9gie th\u00e9rapeutique de l\u2019ataxie de Friedreich.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">* La Commission souhaite la mise en place d\u2019un registre national des patients ayant une ataxie de Friedreich \u00e0 partir de la base BNDMR. La Commission recommande que le recueil des donn\u00e9es soit d\u00e9fini en collaboration \u00e9troite avec les centres de r\u00e9f\u00e9rence et de comp\u00e9tence.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><em>Vous pouvez consulter l\u2019ensemble des documents&nbsp;ici :<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.has-sante.fr\/jcms\/p_4186857\/en\/skyclarys-omaveloxolone-ataxie-de-friedreich-chez-l-adulte-et-l-adolescent-a-partir-de-16-ans\">https:\/\/www.has-sante.fr\/jcms\/p_4186857\/en\/skyclarys-omaveloxolone-ataxie-de-friedreich-chez-l-adulte-et-l-adolescent-a-partir-de-16-ans<\/a><\/p>\n\n\n\n<p class=\"has-text-align-left wp-block-paragraph\">   <strong>_________________________________________________________________________________________________<\/strong><\/p>\n\n\n\n<p class=\"has-vivid-red-color has-text-color has-link-color has-small-font-size wp-elements-5 wp-block-paragraph\"><sup>1<\/sup><sup>&nbsp;<\/sup>Pour \u00eatre achet\u00e9s et utilis\u00e9s \u00e0 l\u2019h\u00f4pital, les m\u00e9dicaments doivent \u00eatre inscrits sur la liste des sp\u00e9cialit\u00e9s pharmaceutiques agr\u00e9\u00e9es \u00e0 l\u2019usage des collectivit\u00e9s et divers services publics. Cette liste est \u00e9tablie par les ministres charg\u00e9s de la sant\u00e9 et de la s\u00e9curit\u00e9 sociale, apr\u00e8s avis de la Haute Autorit\u00e9 de Sant\u00e9 (HAS).<\/p>\n\n\n\n<div class=\"wp-block-group has-background\" style=\"background-color:#f1f2f3\"><div class=\"wp-block-group__inner-container is-layout-constrained wp-block-group-is-layout-constrained\">\n<p class=\"wp-block-paragraph\"><strong><em>D\u00e9finitions\u00a0:<\/em><\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><em><strong>CT\u00a0:<\/strong> Commission de la Transparence. La CT est une instance scientifique compos\u00e9e de m\u00e9decins, pharmaciens, sp\u00e9cialistes en m\u00e9thodologie et \u00e9pid\u00e9miologie et d&#8217;usagers. Elle \u00e9value les m\u00e9dicaments ayant obtenu leur autorisation de mise sur le march\u00e9 (AMM), lorsque le laboratoire qui les commercialise souhaite obtenir leur inscription sur la liste des m\u00e9dicaments remboursables<\/em><\/p>\n\n\n\n<div class=\"wp-block-group\"><div class=\"wp-block-group__inner-container is-layout-constrained wp-block-group-is-layout-constrained\">\n<div class=\"wp-block-group\"><div class=\"wp-block-group__inner-container is-layout-constrained wp-block-group-is-layout-constrained\">\n<p class=\"wp-block-paragraph\"><em><strong>SMR\u00a0:<\/strong> service m\u00e9dical rendu. Crit\u00e8re qui prend en compte la gravit\u00e9 de la pathologie pour laquelle le m\u00e9dicament est indiqu\u00e9 et les donn\u00e9es propres au m\u00e9dicament lui-m\u00eame dans une indication donn\u00e9e.<\/em><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><em>Efficacit\u00e9 et effets ind\u00e9sirables ;<\/em><\/li>\n\n\n\n<li><em>Place dans la strat\u00e9gie th\u00e9rapeutique (notamment au regard des autres th\u00e9rapies disponibles) et existence d\u2019alternatives th\u00e9rapeutiques ;<\/em><\/li>\n\n\n\n<li><em>Int\u00e9r\u00eat pour la sant\u00e9 publique.<\/em><\/li>\n<\/ul>\n<\/div><\/div>\n<\/div><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><em>En fonction de l\u2019appr\u00e9ciation de ces crit\u00e8res, plusieurs niveaux de SMR ont \u00e9t\u00e9 d\u00e9finis :<\/em><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><em>SMR important au majeur<\/em><\/li>\n\n\n\n<li><em>SMR mod\u00e9r\u00e9 ou faible, mais justifiant cependant le remboursement<\/em><\/li>\n\n\n\n<li><em>SMR insuffisant pour justifier une prise en charge par la collectivit\u00e9<\/em><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><em>Le SMR d\u00e9finit le taux de remboursement par l&#8217;Assurance Maladie :<\/em><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><em>Important ou Majeur : Remboursement \u00e0 65 %<\/em><\/li>\n\n\n\n<li><em>Mod\u00e9r\u00e9 : Remboursement \u00e0 30 %<\/em><\/li>\n\n\n\n<li><em>Faible : Remboursement \u00e0 15 %<\/em><\/li>\n\n\n\n<li><em>Insuffisant : Pas de remboursement (0 %)<\/em><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><em>Le SMR d\u2019un m\u00e9dicament est mesur\u00e9 \u00e0 un moment donn\u00e9. Il peut \u00e9voluer dans le temps et son \u00e9valuation se modifier, notamment lorsque des donn\u00e9es nouvelles sur lesquelles son appr\u00e9ciation se fonde sont produites, ou lorsque des alternatives plus efficaces apparaissent.\u00a0<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><em>SMRI Service m\u00e9dical rendu insuffisant.<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><em><strong>ASMR\u00a0:<\/strong> Am\u00e9lioration du service m\u00e9dical rendu. L\u2019ASMR correspond au progr\u00e8s th\u00e9rapeutique apport\u00e9 par un m\u00e9dicament.<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><em>En fonction de l\u2019appr\u00e9ciation, plusieurs niveaux d&#8217;ASMR ont \u00e9t\u00e9 d\u00e9finis :<\/em><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><em>ASMR\u00a0I, majeure,<\/em><\/li>\n\n\n\n<li><em>ASMR II, importante,<\/em><\/li>\n\n\n\n<li><em>ASMR III, mod\u00e9r\u00e9e,<\/em><\/li>\n\n\n\n<li><em>ASMR IV, mineure,<\/em><\/li>\n\n\n\n<li><em>ASMR V, inexistante, signifie \u00ab\u00a0absence de progr\u00e8s th\u00e9rapeutique \u00bb.<\/em><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><em>Le niveau d\u2019ASMR intervient dans la fixation du prix d\u2019un m\u00e9dicament remboursable.<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><em><strong>AMM\u00a0:<\/strong> Autorisation de Mise sur le March\u00e9.<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><em><strong>mFARS<\/strong> (modified Friedreich&#8217;s Ataxia Rating Scale)\u00a0: \u00e9chelle modifi\u00e9e d&#8217;\u00e9valuation de l&#8217;ataxie de Friedreich. \u00a0Outil clinique utilis\u00e9 pour \u00e9valuer la gravit\u00e9 des troubles neurologiques et l&#8217;\u00e9volution de la maladie chez les patients atteints d&#8217;ataxie de Friedreich.<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><em><strong>MOXIe Part 2<\/strong> (NCT02255435)\u00a0: essai clinique multicentrique, en double aveugle et contr\u00f4l\u00e9 par placebo visant \u00e0 \u00e9valuer l\u2019efficacit\u00e9 et la s\u00e9curit\u00e9 de l\u2019omav\u00e9loxolone 150 mg administr\u00e9 une fois par jour pendant 48 semaines, chez des patients atteints d\u2019ataxie de Friedreich \u00e2g\u00e9s de 16 \u00e0 40 ans. L&#8217;omav\u00e9loxolone a am\u00e9lior\u00e9 la fonction neurologique de mani\u00e8re statistiquement significative, \u00e9valu\u00e9e par la variation par rapport \u00e0 la valeur initiale du score mFARS, compar\u00e9 au placebo, et a \u00e9t\u00e9 consid\u00e9r\u00e9 globalement s\u00fbr et bien tol\u00e9r\u00e9.<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><em><strong>BNDMR :<\/strong> Banque Nationale de Donn\u00e9es Maladies Rares. Projet prioritaire du Plan National Maladies Rares 2, financ\u00e9 par le minist\u00e8re de la Sant\u00e9.<\/em><\/p>\n<\/div><\/div>\n","protected":false},"excerpt":{"rendered":"<p>En septembre 2024, la Commission de la Transparence (CT) a rendu un avis favorable au remboursement de Skyclarys, lui accordant un Service M\u00e9dical Rendu (SMR) mod\u00e9r\u00e9 (remboursement \u00e0 30% par l&#8217;Assurance Maladie) et une Am\u00e9lioration du Service M\u00e9dical Rendu (ASMR) V (absence de progr\u00e8s th\u00e9rapeutique). En mai 2026, la CT a r\u00e9alis\u00e9 une \u00e9valuation des [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":9137,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"ocean_front_end_style_editor":"no","ocean_post_layout":"","ocean_both_sidebars_style":"","ocean_both_sidebars_content_width":0,"ocean_both_sidebars_sidebars_width":0,"ocean_sidebar":"0","ocean_second_sidebar":"0","ocean_disable_margins":"enable","ocean_add_body_class":"","ocean_shortcode_before_top_bar":"","ocean_shortcode_after_top_bar":"","ocean_shortcode_before_header":"","ocean_shortcode_after_header":"","ocean_has_shortcode":"","ocean_shortcode_after_title":"","ocean_shortcode_before_footer_widgets":"","ocean_shortcode_after_footer_widgets":"","ocean_shortcode_before_footer_bottom":"","ocean_shortcode_after_footer_bottom":"","ocean_display_top_bar":"default","ocean_display_header":"default","ocean_header_style":"","ocean_center_header_left_menu":"0","ocean_custom_header_template":"0","ocean_custom_logo":0,"ocean_custom_retina_logo":0,"ocean_custom_logo_max_width":0,"ocean_custom_logo_tablet_max_width":0,"ocean_custom_logo_mobile_max_width":0,"ocean_custom_logo_max_height":0,"ocean_custom_logo_tablet_max_height":0,"ocean_custom_logo_mobile_max_height":0,"ocean_header_custom_menu":"0","ocean_menu_typo_font_family":"0","ocean_menu_typo_font_subset":"","ocean_menu_typo_font_size":0,"ocean_menu_typo_font_size_tablet":0,"ocean_menu_typo_font_size_mobile":0,"ocean_menu_typo_font_size_unit":"px","ocean_menu_typo_font_weight":"","ocean_menu_typo_font_weight_tablet":"","ocean_menu_typo_font_weight_mobile":"","ocean_menu_typo_transform":"","ocean_menu_typo_transform_tablet":"","ocean_menu_typo_transform_mobile":"","ocean_menu_typo_line_height":0,"ocean_menu_typo_line_height_tablet":0,"ocean_menu_typo_line_height_mobile":0,"ocean_menu_typo_line_height_unit":"","ocean_menu_typo_spacing":0,"ocean_menu_typo_spacing_tablet":0,"ocean_menu_typo_spacing_mobile":0,"ocean_menu_typo_spacing_unit":"","ocean_menu_link_color":"","ocean_menu_link_color_hover":"","ocean_menu_link_color_active":"","ocean_menu_link_background":"","ocean_menu_link_hover_background":"","ocean_menu_link_active_background":"","ocean_menu_social_links_bg":"","ocean_menu_social_hover_links_bg":"","ocean_menu_social_links_color":"","ocean_menu_social_hover_links_color":"","ocean_disable_title":"default","ocean_disable_heading":"default","ocean_post_title":"","ocean_post_subheading":"","ocean_post_title_style":"","ocean_post_title_background_color":"","ocean_post_title_background":0,"ocean_post_title_bg_image_position":"","ocean_post_title_bg_image_attachment":"","ocean_post_title_bg_image_repeat":"","ocean_post_title_bg_image_size":"","ocean_post_title_height":0,"ocean_post_title_bg_overlay":0.5,"ocean_post_title_bg_overlay_color":"","ocean_disable_breadcrumbs":"default","ocean_breadcrumbs_color":"","ocean_breadcrumbs_separator_color":"","ocean_breadcrumbs_links_color":"","ocean_breadcrumbs_links_hover_color":"","ocean_display_footer_widgets":"default","ocean_display_footer_bottom":"default","ocean_custom_footer_template":"0","ocean_post_oembed":"","ocean_post_self_hosted_media":"","ocean_post_video_embed":"","ocean_link_format":"","ocean_link_format_target":"self","ocean_quote_format":"","ocean_quote_format_link":"post","ocean_gallery_link_images":"on","ocean_gallery_id":[],"footnotes":"[]"},"categories":[43],"tags":[],"class_list":["post-14090","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-informations_recherche","entry","has-media","owp-thumbs-layout-horizontal","owp-btn-normal","owp-tabs-layout-section","has-no-thumbnails"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Avis sur le m\u00e9dicament SKYCLARYS 50mg (omav\u00e9loxolone), g\u00e9lule dans l\u2019Ataxie de Friedreich chez l&#039;adulte et l&#039;adolescent \u00e0 partir de 16 ans, par la Commission de la Transparence (CT) de la HAS du 8 juillet 2026 - Association Fran\u00e7aise Ataxie de Friedreich<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.afaf.asso.fr\/2026\/09\/01\/avis-sur-le-medicament-skyclarys-50mg-omaveloxolone-gelule-dans-lataxie-de-friedreich-chez-ladulte-et-ladolescent-a-partir-de-16-ans-par-la-commission-de-la-transparence-ct-de-la-ha\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Avis sur le m\u00e9dicament SKYCLARYS 50mg (omav\u00e9loxolone), g\u00e9lule dans l\u2019Ataxie de Friedreich chez l&#039;adulte et l&#039;adolescent \u00e0 partir de 16 ans, par la Commission de la Transparence (CT) de la HAS du 8 juillet 2026 - Association Fran\u00e7aise Ataxie de Friedreich\" \/>\n<meta property=\"og:description\" content=\"En septembre 2024, la Commission de la Transparence (CT) a rendu un avis favorable au remboursement de Skyclarys, lui accordant un Service M\u00e9dical Rendu (SMR) mod\u00e9r\u00e9 (remboursement \u00e0 30% par l&#8217;Assurance Maladie) et une Am\u00e9lioration du Service M\u00e9dical Rendu (ASMR) V (absence de progr\u00e8s th\u00e9rapeutique). En mai 2026, la CT a r\u00e9alis\u00e9 une \u00e9valuation des [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.afaf.asso.fr\/2026\/09\/01\/avis-sur-le-medicament-skyclarys-50mg-omaveloxolone-gelule-dans-lataxie-de-friedreich-chez-ladulte-et-ladolescent-a-partir-de-16-ans-par-la-commission-de-la-transparence-ct-de-la-ha\/\" \/>\n<meta property=\"og:site_name\" content=\"Association Fran\u00e7aise Ataxie de Friedreich\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-01T15:12:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-01T15:12:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2023\/07\/Skyclarys.png\" \/>\n\t<meta property=\"og:image:width\" content=\"349\" \/>\n\t<meta property=\"og:image:height\" content=\"144\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Caroline Gaboriau\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Caroline Gaboriau\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2026\\\/09\\\/01\\\/avis-sur-le-medicament-skyclarys-50mg-omaveloxolone-gelule-dans-lataxie-de-friedreich-chez-ladulte-et-ladolescent-a-partir-de-16-ans-par-la-commission-de-la-transparence-ct-de-la-ha\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2026\\\/09\\\/01\\\/avis-sur-le-medicament-skyclarys-50mg-omaveloxolone-gelule-dans-lataxie-de-friedreich-chez-ladulte-et-ladolescent-a-partir-de-16-ans-par-la-commission-de-la-transparence-ct-de-la-ha\\\/\"},\"author\":{\"name\":\"Caroline Gaboriau\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#\\\/schema\\\/person\\\/7366aa03c1779ab28140e42231ed7b28\"},\"headline\":\"Avis sur le m\u00e9dicament SKYCLARYS 50mg (omav\u00e9loxolone), g\u00e9lule dans l\u2019Ataxie de Friedreich chez l&#8217;adulte et l&#8217;adolescent \u00e0 partir de 16 ans, par la Commission de la Transparence (CT) de la HAS du 8 juillet 2026\",\"datePublished\":\"2026-09-01T15:12:32+00:00\",\"dateModified\":\"2026-09-01T15:12:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2026\\\/09\\\/01\\\/avis-sur-le-medicament-skyclarys-50mg-omaveloxolone-gelule-dans-lataxie-de-friedreich-chez-ladulte-et-ladolescent-a-partir-de-16-ans-par-la-commission-de-la-transparence-ct-de-la-ha\\\/\"},\"wordCount\":1431,\"publisher\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2026\\\/09\\\/01\\\/avis-sur-le-medicament-skyclarys-50mg-omaveloxolone-gelule-dans-lataxie-de-friedreich-chez-ladulte-et-ladolescent-a-partir-de-16-ans-par-la-commission-de-la-transparence-ct-de-la-ha\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/Skyclarys.png\",\"articleSection\":[\"Informations sur la recherche\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2026\\\/09\\\/01\\\/avis-sur-le-medicament-skyclarys-50mg-omaveloxolone-gelule-dans-lataxie-de-friedreich-chez-ladulte-et-ladolescent-a-partir-de-16-ans-par-la-commission-de-la-transparence-ct-de-la-ha\\\/\",\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2026\\\/09\\\/01\\\/avis-sur-le-medicament-skyclarys-50mg-omaveloxolone-gelule-dans-lataxie-de-friedreich-chez-ladulte-et-ladolescent-a-partir-de-16-ans-par-la-commission-de-la-transparence-ct-de-la-ha\\\/\",\"name\":\"Avis sur le m\u00e9dicament SKYCLARYS 50mg (omav\u00e9loxolone), g\u00e9lule dans l\u2019Ataxie de Friedreich chez l'adulte et l'adolescent \u00e0 partir de 16 ans, par la Commission de la Transparence (CT) de la HAS du 8 juillet 2026 - Association Fran\u00e7aise Ataxie de Friedreich\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2026\\\/09\\\/01\\\/avis-sur-le-medicament-skyclarys-50mg-omaveloxolone-gelule-dans-lataxie-de-friedreich-chez-ladulte-et-ladolescent-a-partir-de-16-ans-par-la-commission-de-la-transparence-ct-de-la-ha\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2026\\\/09\\\/01\\\/avis-sur-le-medicament-skyclarys-50mg-omaveloxolone-gelule-dans-lataxie-de-friedreich-chez-ladulte-et-ladolescent-a-partir-de-16-ans-par-la-commission-de-la-transparence-ct-de-la-ha\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/Skyclarys.png\",\"datePublished\":\"2026-09-01T15:12:32+00:00\",\"dateModified\":\"2026-09-01T15:12:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2026\\\/09\\\/01\\\/avis-sur-le-medicament-skyclarys-50mg-omaveloxolone-gelule-dans-lataxie-de-friedreich-chez-ladulte-et-ladolescent-a-partir-de-16-ans-par-la-commission-de-la-transparence-ct-de-la-ha\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.afaf.asso.fr\\\/2026\\\/09\\\/01\\\/avis-sur-le-medicament-skyclarys-50mg-omaveloxolone-gelule-dans-lataxie-de-friedreich-chez-ladulte-et-ladolescent-a-partir-de-16-ans-par-la-commission-de-la-transparence-ct-de-la-ha\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2026\\\/09\\\/01\\\/avis-sur-le-medicament-skyclarys-50mg-omaveloxolone-gelule-dans-lataxie-de-friedreich-chez-ladulte-et-ladolescent-a-partir-de-16-ans-par-la-commission-de-la-transparence-ct-de-la-ha\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/Skyclarys.png\",\"contentUrl\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/Skyclarys.png\",\"width\":349,\"height\":144},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2026\\\/09\\\/01\\\/avis-sur-le-medicament-skyclarys-50mg-omaveloxolone-gelule-dans-lataxie-de-friedreich-chez-ladulte-et-ladolescent-a-partir-de-16-ans-par-la-commission-de-la-transparence-ct-de-la-ha\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.afaf.asso.fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Avis sur le m\u00e9dicament SKYCLARYS 50mg (omav\u00e9loxolone), g\u00e9lule dans l\u2019Ataxie de Friedreich chez l&#8217;adulte et l&#8217;adolescent \u00e0 partir de 16 ans, par la Commission de la Transparence (CT) de la HAS du 8 juillet 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#website\",\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/\",\"name\":\"Association Fran\u00e7aise Ataxie de Friedreich\",\"description\":\"Association Fran\u00e7aise de l&#039;Ataxie de Friedreich\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.afaf.asso.fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#organization\",\"name\":\"Association Fran\u00e7aise Ataxie de Friedreich\",\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/Logo-vert.png\",\"contentUrl\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/Logo-vert.png\",\"width\":1181,\"height\":709,\"caption\":\"Association Fran\u00e7aise Ataxie de Friedreich\"},\"image\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#\\\/schema\\\/person\\\/7366aa03c1779ab28140e42231ed7b28\",\"name\":\"Caroline Gaboriau\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8dbf8226706683015a2752bfbf4ecf0bea399e33452121cb9c1f4640fbea214f?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8dbf8226706683015a2752bfbf4ecf0bea399e33452121cb9c1f4640fbea214f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8dbf8226706683015a2752bfbf4ecf0bea399e33452121cb9c1f4640fbea214f?s=96&d=mm&r=g\",\"caption\":\"Caroline Gaboriau\"},\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/author\\\/caroline_gaboriau\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Avis sur le m\u00e9dicament SKYCLARYS 50mg (omav\u00e9loxolone), g\u00e9lule dans l\u2019Ataxie de Friedreich chez l'adulte et l'adolescent \u00e0 partir de 16 ans, par la Commission de la Transparence (CT) de la HAS du 8 juillet 2026 - Association Fran\u00e7aise Ataxie de Friedreich","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.afaf.asso.fr\/2026\/09\/01\/avis-sur-le-medicament-skyclarys-50mg-omaveloxolone-gelule-dans-lataxie-de-friedreich-chez-ladulte-et-ladolescent-a-partir-de-16-ans-par-la-commission-de-la-transparence-ct-de-la-ha\/","og_locale":"fr_FR","og_type":"article","og_title":"Avis sur le m\u00e9dicament SKYCLARYS 50mg (omav\u00e9loxolone), g\u00e9lule dans l\u2019Ataxie de Friedreich chez l'adulte et l'adolescent \u00e0 partir de 16 ans, par la Commission de la Transparence (CT) de la HAS du 8 juillet 2026 - Association Fran\u00e7aise Ataxie de Friedreich","og_description":"En septembre 2024, la Commission de la Transparence (CT) a rendu un avis favorable au remboursement de Skyclarys, lui accordant un Service M\u00e9dical Rendu (SMR) mod\u00e9r\u00e9 (remboursement \u00e0 30% par l&#8217;Assurance Maladie) et une Am\u00e9lioration du Service M\u00e9dical Rendu (ASMR) V (absence de progr\u00e8s th\u00e9rapeutique). En mai 2026, la CT a r\u00e9alis\u00e9 une \u00e9valuation des [&hellip;]","og_url":"https:\/\/www.afaf.asso.fr\/2026\/09\/01\/avis-sur-le-medicament-skyclarys-50mg-omaveloxolone-gelule-dans-lataxie-de-friedreich-chez-ladulte-et-ladolescent-a-partir-de-16-ans-par-la-commission-de-la-transparence-ct-de-la-ha\/","og_site_name":"Association Fran\u00e7aise Ataxie de Friedreich","article_published_time":"2026-09-01T15:12:32+00:00","article_modified_time":"2026-09-01T15:12:36+00:00","og_image":[{"width":349,"height":144,"url":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2023\/07\/Skyclarys.png","type":"image\/png"}],"author":"Caroline Gaboriau","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Caroline Gaboriau","Dur\u00e9e de lecture estim\u00e9e":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.afaf.asso.fr\/2026\/09\/01\/avis-sur-le-medicament-skyclarys-50mg-omaveloxolone-gelule-dans-lataxie-de-friedreich-chez-ladulte-et-ladolescent-a-partir-de-16-ans-par-la-commission-de-la-transparence-ct-de-la-ha\/#article","isPartOf":{"@id":"https:\/\/www.afaf.asso.fr\/2026\/09\/01\/avis-sur-le-medicament-skyclarys-50mg-omaveloxolone-gelule-dans-lataxie-de-friedreich-chez-ladulte-et-ladolescent-a-partir-de-16-ans-par-la-commission-de-la-transparence-ct-de-la-ha\/"},"author":{"name":"Caroline Gaboriau","@id":"https:\/\/www.afaf.asso.fr\/#\/schema\/person\/7366aa03c1779ab28140e42231ed7b28"},"headline":"Avis sur le m\u00e9dicament SKYCLARYS 50mg (omav\u00e9loxolone), g\u00e9lule dans l\u2019Ataxie de Friedreich chez l&#8217;adulte et l&#8217;adolescent \u00e0 partir de 16 ans, par la Commission de la Transparence (CT) de la HAS du 8 juillet 2026","datePublished":"2026-09-01T15:12:32+00:00","dateModified":"2026-09-01T15:12:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.afaf.asso.fr\/2026\/09\/01\/avis-sur-le-medicament-skyclarys-50mg-omaveloxolone-gelule-dans-lataxie-de-friedreich-chez-ladulte-et-ladolescent-a-partir-de-16-ans-par-la-commission-de-la-transparence-ct-de-la-ha\/"},"wordCount":1431,"publisher":{"@id":"https:\/\/www.afaf.asso.fr\/#organization"},"image":{"@id":"https:\/\/www.afaf.asso.fr\/2026\/09\/01\/avis-sur-le-medicament-skyclarys-50mg-omaveloxolone-gelule-dans-lataxie-de-friedreich-chez-ladulte-et-ladolescent-a-partir-de-16-ans-par-la-commission-de-la-transparence-ct-de-la-ha\/#primaryimage"},"thumbnailUrl":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2023\/07\/Skyclarys.png","articleSection":["Informations sur la recherche"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.afaf.asso.fr\/2026\/09\/01\/avis-sur-le-medicament-skyclarys-50mg-omaveloxolone-gelule-dans-lataxie-de-friedreich-chez-ladulte-et-ladolescent-a-partir-de-16-ans-par-la-commission-de-la-transparence-ct-de-la-ha\/","url":"https:\/\/www.afaf.asso.fr\/2026\/09\/01\/avis-sur-le-medicament-skyclarys-50mg-omaveloxolone-gelule-dans-lataxie-de-friedreich-chez-ladulte-et-ladolescent-a-partir-de-16-ans-par-la-commission-de-la-transparence-ct-de-la-ha\/","name":"Avis sur le m\u00e9dicament SKYCLARYS 50mg (omav\u00e9loxolone), g\u00e9lule dans l\u2019Ataxie de Friedreich chez l'adulte et l'adolescent \u00e0 partir de 16 ans, par la Commission de la Transparence (CT) de la HAS du 8 juillet 2026 - Association Fran\u00e7aise Ataxie de Friedreich","isPartOf":{"@id":"https:\/\/www.afaf.asso.fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.afaf.asso.fr\/2026\/09\/01\/avis-sur-le-medicament-skyclarys-50mg-omaveloxolone-gelule-dans-lataxie-de-friedreich-chez-ladulte-et-ladolescent-a-partir-de-16-ans-par-la-commission-de-la-transparence-ct-de-la-ha\/#primaryimage"},"image":{"@id":"https:\/\/www.afaf.asso.fr\/2026\/09\/01\/avis-sur-le-medicament-skyclarys-50mg-omaveloxolone-gelule-dans-lataxie-de-friedreich-chez-ladulte-et-ladolescent-a-partir-de-16-ans-par-la-commission-de-la-transparence-ct-de-la-ha\/#primaryimage"},"thumbnailUrl":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2023\/07\/Skyclarys.png","datePublished":"2026-09-01T15:12:32+00:00","dateModified":"2026-09-01T15:12:36+00:00","breadcrumb":{"@id":"https:\/\/www.afaf.asso.fr\/2026\/09\/01\/avis-sur-le-medicament-skyclarys-50mg-omaveloxolone-gelule-dans-lataxie-de-friedreich-chez-ladulte-et-ladolescent-a-partir-de-16-ans-par-la-commission-de-la-transparence-ct-de-la-ha\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.afaf.asso.fr\/2026\/09\/01\/avis-sur-le-medicament-skyclarys-50mg-omaveloxolone-gelule-dans-lataxie-de-friedreich-chez-ladulte-et-ladolescent-a-partir-de-16-ans-par-la-commission-de-la-transparence-ct-de-la-ha\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.afaf.asso.fr\/2026\/09\/01\/avis-sur-le-medicament-skyclarys-50mg-omaveloxolone-gelule-dans-lataxie-de-friedreich-chez-ladulte-et-ladolescent-a-partir-de-16-ans-par-la-commission-de-la-transparence-ct-de-la-ha\/#primaryimage","url":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2023\/07\/Skyclarys.png","contentUrl":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2023\/07\/Skyclarys.png","width":349,"height":144},{"@type":"BreadcrumbList","@id":"https:\/\/www.afaf.asso.fr\/2026\/09\/01\/avis-sur-le-medicament-skyclarys-50mg-omaveloxolone-gelule-dans-lataxie-de-friedreich-chez-ladulte-et-ladolescent-a-partir-de-16-ans-par-la-commission-de-la-transparence-ct-de-la-ha\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.afaf.asso.fr\/"},{"@type":"ListItem","position":2,"name":"Avis sur le m\u00e9dicament SKYCLARYS 50mg (omav\u00e9loxolone), g\u00e9lule dans l\u2019Ataxie de Friedreich chez l&#8217;adulte et l&#8217;adolescent \u00e0 partir de 16 ans, par la Commission de la Transparence (CT) de la HAS du 8 juillet 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.afaf.asso.fr\/#website","url":"https:\/\/www.afaf.asso.fr\/","name":"Association Fran\u00e7aise Ataxie de Friedreich","description":"Association Fran\u00e7aise de l&#039;Ataxie de Friedreich","publisher":{"@id":"https:\/\/www.afaf.asso.fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.afaf.asso.fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.afaf.asso.fr\/#organization","name":"Association Fran\u00e7aise Ataxie de Friedreich","url":"https:\/\/www.afaf.asso.fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.afaf.asso.fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/06\/Logo-vert.png","contentUrl":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/06\/Logo-vert.png","width":1181,"height":709,"caption":"Association Fran\u00e7aise Ataxie de Friedreich"},"image":{"@id":"https:\/\/www.afaf.asso.fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.afaf.asso.fr\/#\/schema\/person\/7366aa03c1779ab28140e42231ed7b28","name":"Caroline Gaboriau","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/8dbf8226706683015a2752bfbf4ecf0bea399e33452121cb9c1f4640fbea214f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8dbf8226706683015a2752bfbf4ecf0bea399e33452121cb9c1f4640fbea214f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8dbf8226706683015a2752bfbf4ecf0bea399e33452121cb9c1f4640fbea214f?s=96&d=mm&r=g","caption":"Caroline Gaboriau"},"url":"https:\/\/www.afaf.asso.fr\/author\/caroline_gaboriau\/"}]}},"_links":{"self":[{"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/posts\/14090","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/comments?post=14090"}],"version-history":[{"count":19,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/posts\/14090\/revisions"}],"predecessor-version":[{"id":14109,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/posts\/14090\/revisions\/14109"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/media\/9137"}],"wp:attachment":[{"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/media?parent=14090"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/categories?post=14090"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/tags?post=14090"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}